B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
SNDX
SyndaxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Revuforj growth and the remaining cGVHD program could support recovery despite the lost IPF opportunity. Q2 Syndax revenue was $72.8 million, including $54.7 million of Revuforj revenue and $18.1 million of Niktimvo collaboration revenue—not the full $60.3 million of Niktimvo product sales reported by partner Incyte.
Posture
Defensive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-10-26.
What can break
MAXPIRe missed its primary endpoint; Syndax has ended axatilimab development in IPF. [#PR-2026-10-12] https://syndaxpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/syndax-announces-topline-results-maxpire-phase-2-trial
Momentum
9
Value
41
Sentiment
63
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $15.00 · Bull $19.00 · Bear $9.50Analysis 2026-10-14; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $37.27
Why
Momentum9 · Δ7d -7.9
Value41 · Δ7d -0.1
Sentiment63 · Δ7d -4.6
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-26.
- • Next scheduled catalyst: earnings 2026-10-29.
- • Sentiment remains the lead driver in the composite, 7D delta -4.6.
Contradictions & invalidation
- • MAXPIRe missed its primary endpoint; Syndax has ended axatilimab development in IPF. [#PR-2026-10-12] https://syndaxpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/syndax-announces-topline-results-maxpire-phase-2-trial
- • Niktimvo product sales are recorded by Incyte; Syndax recognizes collaboration revenue based on its share of net commercial profit, so product sales cannot be added directly to Syndax revenue. [#SEC-8K-2026-08-04]
- • The IPF failure removes a pipeline expansion opportunity and increases reliance on Revuforj execution and cGVHD readouts.
Catalyst clock
2026-10-29
Repricing after the MAXPIRe IPF failure
Lead driver: Sentiment · See AI snapshot
Momentum
9
8% active weight
Current posture
7d trendSoftening
Δ7d
-7.9
Δ21d
-17.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
63
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.6
Δ21d
-28.2
Why this grade
Composite grade D. Momentum 8.9 / Value 40.6 / Sentiment 62.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$1.18B
Beta
0.46
Shares Out
89.3M
P/E (TTM) · Derived
-4.0
P/S (TTM)
15.75
P/FCF (TTM) · Derived
-5.24
Rev YoY
+91.8%
EPS YoY
-33.3%
Gross Margin
+95.8%
Op Margin
-77.0%
Net Debt
-$48.64M
Current Ratio
6.77
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data